Edition:
United States

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

6,049JPY
21 Jul 2017
Change (% chg)

¥-12 (-0.20%)
Prev Close
¥6,061
Open
¥6,041
Day's High
¥6,051
Day's Low
¥6,006
Volume
581,700
Avg. Vol
777,420
52-wk High
¥7,280
52-wk Low
¥5,581

4523.T

Chart for 4523.T

About

Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's businesses include pharmaceutical business and other business. The Company's segments include Japan (Prescription Medicines, Generics and Diagnostics), Americas (North America, Central and South... (more)

Overall

Beta: 0.67
Market Cap(Mil.): ¥1,793,934.00
Shares Outstanding(Mil.): 296.57
Dividend: 70.00
Yield (%): 2.48

Financials

  4523.T Industry Sector
P/E (TTM): 44.02 11.79 15.85
EPS (TTM): 137.42 -- --
ROI: 5.26 -10.04 -8.31
ROE: 6.80 -9.89 -7.95

BRIEF-Oncology Venture and Eisai forge exclusive global license agreement for clinical stage oncology drug PARP inhibitor E7449 / 2X-121

* ‍Oncology Venture - Co entered into exclusive global license agreement with Eisai Inc. for Eisai's phase 2 parp inhibitor E7449 - now called 2X-121​

Jul 07 2017

BRIEF-Oncology Venture Sweden and Eisai sign exclusive global license agreement

* ONCOLOGY VENTURE AND EISAI FORGE EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR CLINICAL STAGE ONCOLOGY DRUG PARP INHIBITOR E7449 / 2X-121 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 07 2017

BRIEF- R&I affirms Eisai's rating at "A+" and announces stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I

Jun 30 2017

BRIEF-Ewopharma announces commercial partnership with Eisai

* Ewopharma says it will commercialise Halaven (eribulin mesylate) in nine countries within European Union and in two countries outside of EU

Jun 22 2017

BRIEF-Positive topline results show Eisai's Lenvatinib meets primary endpoint

* Positive topline results of large phase 3 trial show Eisai's lenvatinib meets primary endpoint in unresectable hepatocellular carcinoma

Jan 25 2017

Earnings vs. Estimates